Biogen Inc. (BVMF:BIIB34)

Market Cap	141.14B +15.6%
Revenue (ttm)	54.48B +2.2%
Net Income	7.12B -20.8%
EPS	48.42 -21.4%
Shares Out	n/a
PE Ratio	19.82
Forward PE	11.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	42
Open	162.59
Previous Close	162.59
Day's Range	162.59 - 162.59
52-Week Range	110.07 - 172.26
Beta	0.15
RSI	53.50
Earnings Date	Apr 30, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,500
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIIB34

Financial Performance

In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.

Financial numbers in USD